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The clinical use of antipsychotic drugs 
especially the high potency agents like 
haloperidol, trifluperazine and emergence 
of extra-pyramidal symptoms like pseudo-
parkinsonism and acute dystorias. Since 
these may effect drug compliance adverse-
ly atropine like antiparkinsonian agents 
have at time, been prescribed routinely for 
prophylaxis. Studies to resolve this issue 
have mostly taken patients already on 
phenothiazines (Klatt and Caffey, 1972; 
Orlow et ah, 1972). A prospective study 
by Holou and colleagues (1966) has the 
drawback of different neuroleptic doses in 
the experimental and control groups. 
The study reported here aimed to 
assess the relative efficacy of trifluperazine 
(TFP) against the Trifluperazine-trihexy-
phenidyl (TFP-THP) combination and to 
determine the difference in side effects. 
The sample consisted of 30 patients with 
a Research Diagnostic Criteria (Feighner 
et al., 1972) diagnosis of schizophrenic 
psychosis aged between 17 and 55 years 
with no evidence of organic brain damage 
or any severe physical illness. Those 
having received oral antipsychotic/anti-
parkinsonian drugs in the past one week 
and/or ECT or depot neuroleptics in the 
last fortnight were excluded. The study 
followed a double blind parallel metho-
dology on a fixed dose schedule with TFP 
and TFP-THP in identical tablets (5mg 
TFP and 2 mg THP). Evaluations were 
on the Brief Psychiatric Rating Scale 
side effects symptoms checklist and 
C. G. I. S. which were all administered 
baseline and weekly till the end of study 
at 4 weeks. 
RESULTS AND DISCUSSION 
Our findings indicate that the combi-
nation of an antiparkinsonian agent does 
not reduce clinical efficacy of triflupera-
TABLE 1. Sample Characteristics 
Age Sex Base line 
BPRS Scores 
Male Female 
TFP 26.86±7.99 10 4 42.29±4.67 
(71.43) (28.57) 
TFP-THP 24.64±5.95 8 6 40.64±4.31 
(57.14) (42.86) 
TABLE 2.  BPRS Scores—Improvements 
ASSESSMENTS 
I II III IV 
Mean 4.57 8.57 13.00 15-93 
TFP 
SD 2.59 2.95 4.46 5.06 
Mean 4.0 9.29 11.71 14.50 
TFP-THP 
SD 2.59 4.37 5.26 1.92 
AH Insignificant. 
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SIDE EFFECTS 
Trifluperazine Trifluperazine-
Benzhexol 
1. Rigidity 
2. Dry Mouth 
3. Perspiration 
4. Akathisia 
5. Involuntary Move-
ments 
6. Muscle spasm 
7. Flushing 
8. Tremors 
9. Light Headedness 
10. Dizzinese 
11. Masking 
12. Dystonia Body 
13. Drowsiness 
14. Confusion 
15. Salivation 
Total 
Total patients 
Excl. Dry Mouth 
N=15 N=15 
5 (35.31) 
3 (21.43) 4 (28.57) 
4 (28.57) 
7(50.00) 2(14.28) 
4 (28.57) 
4 (28.57) 
5 (35.71) 1 (7.14) 
32 7 
9 (68.28) 5 (35.71) 
6 (42.85) 1 (7.14) 
zine to any significant extent at any of 
the weekly assessments. The incidence of 
side effects is lower in the group receiving 
the combination whereas rigidity and mus-
cle spasm are entirely absent. Of the 
patients receiving TFP-THP only 35.7% 
showed any side effects compared to 68.2% 
in the other group. 
Of the side effects listed, dryness of 
mouth can be caused by the THP and is 
seen to occur in 4 patieats in the combi-
nation ^roup whereas only in 3 in the TFP 
group. On this being excluded the inci-
dence of side effects becomes 7.1 % and 
42.8% respectively, a result which is statis 
tically significant. We may therefore 
enclude that while addition of Trihexy-
phenidyl to trifluperazine does not appear 
to lower the clincal efficacy, the incidence 
of disturbing extrapyramidal side effects 
is considerably less. 
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